Expert flags concerns over 'bananas' 340B program growth and oversight | Asembia AXS26 Summit

The 340B Drug Pricing Program has become a central force in the U.S. drug market, allowing certain hospitals and clinics to purchase medications at steep discounts. Originally designed to support providers serving low-income and vulnerable patients, the program has expanded rapidly in recent years and is now projected to become one of the largest federal drug programs in 2027, according to Lindsay Greenleaf, J.D., MBA, from ADVI Health, a consulting firm for healthcare and pharmaceutical companies.

In this conversation, she explains why she believes this program has gotten “out of hand.”

“One in four drugs in America is purchased at a steeply discounted 340B price. It's bananas,” Greenleaf said in a recent Managed Healthcare Executive interview.

Greenleaf continued by saying that 340B comes up in every client conversation at ADVI Health, especially with their manufacturer clients.

“There’s a request for information underway right now from the Health Resources and Services Administration. We hope that moves along quickly and can be expanded to the program at large.”

Greenleaf presented yesterday at Asembia’s 2026 Specialty Pharmacy Summit, being held in Las Vegas from April 26 to April 30.

She spoke during a session called, “Evolving U.S. Policy and Value Economics: Shaping the Future of Specialty.”